The Pharmaceutical Benefits Scheme will subsidise nirsevimab for high-risk premature infants from October 1, giving neonatal units a long-acting antibody option before winter respiratory syncytial virus season peaks.
Health Minister Mark Butler announced the listing in August; pharmacies and hospitals confirmed stock positions this week after cold-chain shipments reached state depots. Eligible babies born before 37 weeks gestation or with certain congenital heart conditions can receive a single dose before discharge or at outpatient clinics.
Clinical case
RSV remains the leading cause of infant hospitalisation in Australia. Palivizumab required monthly injections and was limited to the highest-risk cohorts. Nirsevimab's extended half-life promises one-season protection with fewer clinic visits, easing burden on families in regional areas far from paediatric centres.
The listing does not yet cover all term infants; broader population programs are under cost-effectiveness review.Paediatricians welcomed the move but urged clear communication so parents do not confuse the antibody with routine vaccines recorded on the Australian Immunisation Register.
Hospital planning
Perth Children's Hospital and Sydney's Westmead have updated admission protocols to track RSV positives separately from influenza as both viruses circulate. Ward managers stockpiled cribs and oxygen circuits after last year's June surge strained emergency departments.
The Royal Australian College of General Practitioners published quick-reference guides for GPs whose patients graduate from hospital follow-up but still carry respiratory risk.
Cost and access
Without PBS support, the dose could cost families more than a thousand dollars. The listing sets a patient copayment for general patients and safety-net rates for concession holders. Pharmaceutical companies agreed to volume rebates tied to uptake reporting, a standard PBS confidentiality arrangement.
Authorities will monitor real-world effectiveness through hospital surveillance networks and adjust eligibility if breakthrough infections cluster in specific gestational age bands.
Pharmacy rollout
Hospital pharmacies verified cold-chain loggers on shipments arriving from Sydney and Melbourne depots. Community pharmacies near tertiary nurseries registered to administer outpatient doses where paediatricians authorise scripts.
Indigenous health services in the Northern Territory requested extra transport coolers for fly-in clinics; the department is assessing requests against existing vaccine programs. Midwives received scripting guides distinguishing nirsevimab from routine childhood immunisations recorded on blue books.
Winter 2025 hospitalisation data will benchmark whether the listing reduces intensive-care stays; analysts expect measurable declines only in cohorts with complete uptake.
State coordination
Queensland Health aligned hospital formularies with the PBS listing within 48 hours, while Western Australia scheduled webinars for rural paediatricians who refer into Perth tertiary centres.
Insurance funds asked whether the antibody affects premium calculations for family policies; regulators said listed medicines should not trigger underwriting changes for infants covered under parental plans.